A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
Background - This study compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP) in small-cell lung cancer patients with extensive disease. - Patients and methods - Patients were randomly assigned to receive cisplatin 80 mg/m2 and either irinotecan 65 mg/m2, days 1 and 8 or etoposi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2010
|
| In: |
Annals of oncology
Year: 2010, Jahrgang: 21, Heft: 9, Pages: 1810-1816 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdq036 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdq036 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419400598 
|
| Verfasserangaben: | P. Zatloukal, F. Cardenal, A. Szczesna, V. Gorbunova, V. Moiseyenko, X. Zhang, L. Cisar, J. -C. Soria, M. Domine & M. Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1886034699 | ||
| 003 | DE-627 | ||
| 005 | 20240703165230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240417s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdq036 |2 doi | |
| 035 | |a (DE-627)1886034699 | ||
| 035 | |a (DE-599)KXP1886034699 | ||
| 035 | |a (OCoLC)1443668890 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zatloukal, Petr |e VerfasserIn |0 (DE-588)1280856149 |0 (DE-627)1834873924 |4 aut | |
| 245 | 1 | 2 | |a A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease |c P. Zatloukal, F. Cardenal, A. Szczesna, V. Gorbunova, V. Moiseyenko, X. Zhang, L. Cisar, J. -C. Soria, M. Domine & M. Thomas |
| 264 | 1 | |c September 2010 | |
| 300 | |b 1 Diagramm | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.04.2024 | ||
| 520 | |a Background - This study compared irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP) in small-cell lung cancer patients with extensive disease. - Patients and methods - Patients were randomly assigned to receive cisplatin 80 mg/m2 and either irinotecan 65 mg/m2, days 1 and 8 or etoposide 100 mg/m2, days 1-3, every 3 weeks. - Results - Baseline characteristics were balanced between patients receiving IP (N = 202) or EP (N = 203). Median overall survival was nonsignificantly superior for patients receiving IP versus EP, 10.2 versus 9.7 months [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.65-1.01, P = 0.06] and 1- and 2-year survival rates were 41.9% versus 38.9% and 16.3% versus 8.2%, respectively. Noninferiority of IP versus EP was established, upper bound of the 95% CI of HR 1.01 (prespecified margin IP/EP <1.25). Overall response (39.1% versus 46.6%) and time to tumor progression (5.4 versus 6.2 months) were not superior for IP. Grade 3/4 vomiting (10.9% versus 4.4%) and diarrhea (15.4% versus 0.5%) were more common in the IP versus EP arm; grade 3/4 neutropenia was more frequent in the EP (59.6%) versus IP arm (38.1%). - Conclusions - Our data demonstrate the noninferiority of IP versus EP for survival in primarily Western patients with SCLC-ED. A meta-analysis is required to finally assess the role of irinotecan in this setting. | ||
| 650 | 4 | |a cisplatin | |
| 650 | 4 | |a etoposide | |
| 650 | 4 | |a irinotecan | |
| 650 | 4 | |a small-cell lung cancer with extensive disease | |
| 700 | 1 | |a Cardenal, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Szczesna, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gorbunova, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moiseyenko, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zhang, X. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cisar, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soria, J. -C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Domine, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 21(2010), 9 vom: Sept., Seite 1810-1816 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease |
| 773 | 1 | 8 | |g volume:21 |g year:2010 |g number:9 |g month:09 |g pages:1810-1816 |g extent:7 |a A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease |
| 856 | 4 | 0 | |u https://doi.org/10.1093/annonc/mdq036 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753419400598 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240417 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 50000 |d 910000 |d 950000 |d 950900 |e 50000PT1054438781 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/50000/ |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 10 |y j | ||
| 999 | |a KXP-PPN1886034699 |e 4512838015 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"id":{"issn":["1569-8041"],"zdb":["2003498-2"],"eki":["320428796"]},"language":["eng"],"recId":"320428796","origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"pubHistory":["1.1990 -"],"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"part":{"extent":"7","volume":"21","issue":"9","pages":"1810-1816","year":"2010","text":"21(2010), 9 vom: Sept., Seite 1810-1816"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive diseaseAnnals of oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}]}],"recId":"1886034699","origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"September 2010"}],"note":["Gesehen am 17.04.2024"],"id":{"doi":["10.1093/annonc/mdq036"],"eki":["1886034699"]},"physDesc":[{"noteIll":"1 Diagramm","extent":"7 S."}],"person":[{"role":"aut","given":"Petr","display":"Zatloukal, Petr","family":"Zatloukal"},{"family":"Cardenal","role":"aut","display":"Cardenal, F.","given":"F."},{"role":"aut","display":"Szczesna, A.","given":"A.","family":"Szczesna"},{"family":"Gorbunova","given":"V.","display":"Gorbunova, V.","role":"aut"},{"family":"Moiseyenko","display":"Moiseyenko, V.","given":"V.","role":"aut"},{"display":"Zhang, X.","given":"X.","role":"aut","family":"Zhang"},{"role":"aut","given":"L.","display":"Cisar, L.","family":"Cisar"},{"family":"Soria","role":"aut","display":"Soria, J. -C.","given":"J. -C."},{"family":"Domine","role":"aut","display":"Domine, M.","given":"M."},{"family":"Thomas","role":"aut","given":"Michael","display":"Thomas, Michael"}],"title":[{"title":"A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease","title_sort":"multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["P. Zatloukal, F. Cardenal, A. Szczesna, V. Gorbunova, V. Moiseyenko, X. Zhang, L. Cisar, J. -C. Soria, M. Domine & M. Thomas"]},"language":["eng"]} | ||
| SRT | |a ZATLOUKALPMULTICENTE2010 | ||